CNBC's Susan Li asks Abraham Chan, founder, chairman, CEO and executive director of PuraPharm, whether he is worried about how the recent market rout may affect the company's listing in Hong Kong.» Read More
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Tree huggers (just a colloquialism, not a dig) will be glad to know that biopharmaceutical companies submit their Food and Drug Administration filings for drug approval electronically these days.
Walgreen posted a 2 percent increase in quarterly profit as sales were muted by a weak U.S. economy and slowing growth in prescription drug sales.
As much as I tried to disconnect during my vacation last week, I couldn't escape the ubiquitous presence of pharmaceuticals in our everyday lives...
On Tuesday we received word of three exciting medical advancements. Find out what’s happening and how to trade them.
I had a visit on Power Lunch today and we talked about the effect on the health care stocks depending on who wins the White House. In general, pharmaceutical companies do well when they have a new product pipeline of innovative products that allow them to command high prices.
It never ceases to amaze me who reads Pharma's Market. Like the Stanford University professor who wrote to set the record straight regarding my coverage from ASCO of the brain cancer vaccine from Pfizer and Avant.
Pfizer may bid for Ranbaxy Laboratories, countering a $4.6 billion offer by Japan's DaiichiSankyo Co for the Indian generic drug maker, the Business Standard newspaper said.
I'm at the Needham & Company biotech conference in New York City. Whenever possible I like to attend events like this. It's a good place to get story ideas. The Needham meeting is competing this year with a similar one being put on by Goldman Sachs in Laguna Beach, CA.
Pfizer shares continue to trade at new nearly 11-year lows over concerns the dividend might get cut, in addition to the lack of anything visible to replace Lipitor when it goes generic in a couple years or so. But on two of the op-ed pages in Wednesday's "Wall Street Journal" Pfizer got a plug.
Cancer, diabetes and Alzheimer's Disease. Three of the biggest areas of unmet medical need have been or will be in focus at a series of important scientific meetings in June or July.
Japanese drug maker Daiichi Sankyo will pay up to $4.6 billion for control of India's Ranbaxy Laboratories, the latest in a string of global health deals as firms look to bulk up and diversify to fend off aggressive rivals.
First, last Friday, Novo Nordisk put out a press release saying preliminary data show its drug works better than Byetta. And then, yesterday an analyst downgraded the stock just ahead of the company's long anticipated release of long-term results on its once-a-week version of Byetta.
We are covering the ADA meeting today and tomorrow because most of the major data came out over the weekend or is coming out later today. Or so we thought.
"You continue--day after day--to knock the company at every opportunity. I understand you had a difficult relationship with the CEO before, but you shouldn't hold a grudge against the company for it..."
Despite at least a couple of analysts coming out with relatively bullish post-ASCO research notes on Pfizer's oncology drug pipeline, PFE shares have fallen to yet another new low intra-day and have crossed another threshold.
Switzerland’s leading stock index, the SMI, has fallen more than 21 percent over the last twelve months, but investment opportunities are emerging with certain large-cap well-positioned stocks such as Roche and Swatch, Maximilian Muench, head of Swiss equities research at UBS told CNBC.
This year, for the first time ever, ASCO agreed to let CNBC broadcast live from inside McCormick Place. It took years of reasoning, pleading, nagging and complaining to get inside. But finally, ASCO consented. In the past, the scientific organization has tried to keep more than an arm's distance from the financial media.
Stocks closed lower Monday, snapping last week's rally, amid a fresh wave of financial worries and inflation concerns. General Motors rose.
Stocks declined amid concerns about inflation following a manufacturing report and a fresh wave of concerns in the financial sector.